Advertisement

Topics

Ark Biosciences Partners with Calibr on Novel COPD Treatment

03:05 EST 10 Nov 2017 | ChinaBio Today

Ark Biosciences of Shanghai partnered with the California Institute for Biomedical Research (Calibr) of La Jolla to develop first-in-class therapies for chronic obstructive pulmonary disease and related lung diseases. Based on its breakthrough in synthesizing boronic acids, Calibr constructed a compound to inhibit neutrophil elastase, the cause of damage in COPD, cystic fibrosis and other respiratory ailments. Calibr is an affiliate of The Scripps Research Institute. Ark, a specialist in viral infection and respiratory diseases, will be responsible for preclinical and clinical development of the molecule. More details....

Share this with colleagues:

Original Article: Ark Biosciences Partners with Calibr on Novel COPD Treatment

NEXT ARTICLE

More From BioPortfolio on "Ark Biosciences Partners with Calibr on Novel COPD Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...